#cber
UC Berkeley professor wins Nobel Prize for groundbreaking quantum research
A UC Berkeley physicist has joined the ranks of Nobel laureates after being recognized for groundbreaking work that expanded the frontiers of quantum mechanics. John Clarke, an emeritus professor of physics at the University of California, Berkeley, has been awarded the Nobel Prize in Physics for his pioneering experiments that reshaped the scientific understanding of how particles behave on a macroscopic level. Clarke shares the honor with Michel H. Devoret and John M. Martinis of the Univer
UC Berkeley professor wins Nobel Prize for groundbreaking quantum research
A UC Berkeley physicist has joined the ranks of Nobel laureates after being recognized for groundbreaking work that expanded the frontiers of quantum mechanics. John Clarke, an emeritus professor of physics at the University of California, Berkeley, has been awarded the Nobel Prize in Physics for his pioneering experiments that reshaped the scientific understanding of how particles behave on a macroscopic level. Clarke shares the honor with Michel H. Devoret and John M. Martinis of the Univer
FDA names Vinay Prasad as head of CBER, known for bold public health views
Vinay Prasad, a renowned oncologist-hematologist, has been appointed as the new director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA). This division of the FDA is charged with overseeing the evaluation and approval of critical biologic products, including vaccines, blood derivatives, and select gene-based therapies. Prasad’s appointment comes at a time when the FDA remains under public and political scrutiny for its handling of
FDA names Vinay Prasad as head of CBER, known for bold public health views
Vinay Prasad, a renowned oncologist-hematologist, has been appointed as the new director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA). This division of the FDA is charged with overseeing the evaluation and approval of critical biologic products, including vaccines, blood derivatives, and select gene-based therapies. Prasad’s appointment comes at a time when the FDA remains under public and political scrutiny for its handling of









